openPR Logo
Press release

Autologous Cell Therapy Market Worth US$ 23.7 Bn by 2024

02-20-2017 02:44 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Autologous Cell Therapy Market Worth US$ 23.7 Bn by 2024

Global Autologous Cell Therapy Market: Overview

Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell therapy does not even require immunosuppression. The growing number of cancer patients have triggered a significant demand for autologous cell therapy. According to the research report, the global market projected to reach a valuation of US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.

Obtain the Sample containing Upcoming Market Analysis of Autologous Cell Therapy at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=715

Unmet Medical Needs and Cost-effectiveness of Autologous Cell Therapy Drives Demand

The global market is expected to grow due to the huge pool of unmet medical needs for cell based therapy, growing government support for cell-based research, and rising number of technological innovations in cell based therapies. Currently, cell therapy is considered a promising technique for several conditions such as neurological, orthopedic, oncology, and a wide range of autoimmune diseases. The ability of stem cells to transform into a cartilage, tendon, bone (osteoblast), and muscle has given this market a fresh lease of life. The biggest advantages of autologous cells is the fact that it is relatively cost-effective, allows quick access to blood as it is derived from the patient, ensures easy method of production, and comes with the lowest threat of disease transfusion. All of these factors have been consistently boosting the demand for autologous cell therapy in recent years.

Supportive Government Policies across North America Favor Regional Market

Geographically, the market has been divided into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. North America holds a dominant position in the global market and is expected to maintain its stance in the coming years as well. The strengthening health care infrastructure and supportive government policies are expected ensure high adoption of autologous cell therapy in North America in the near future. The analysts estimate that Asia Pacific will also register a robust CAGR in the coming years. The growth of this market in Asia pacific will be driven by the proliferating medical tourism industry, increasing contract research activities, and economic growth of certain developing countries such as India and China.

Hospitals to Retain Dominance in Global Market over Forecast Period

The end users of autologous cell therapy are hospitals, research centers, and ambulatory centers. Of these, the hospitals dominated the global market in 2015 and are expected to continue its dominance till the end of 2024 as the surgical procedures continue to be on the rise across hospitals. The research report indicates that the ambulatory surgical centers segment will also expand at a significant rate in the coming years as it is known to reduce waiting time period before surgery, growing outpatient surgical procedures, high confidentiality and privacy of the data, and cost-effective procedure.

Read the Present Market Status of Autologous Cell Therapy at: http://www.transparencymarketresearch.com/autologus-cell-therapy-market.html

Some of the leading players operating in the global market are Major players operating in this Market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Autologous Cell Therapy Market Worth US$ 23.7 Bn by 2024 here

News-ID: 442846 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Autologous

Autologous Cell Therapy Market: Competitive Dynamics & Global Outlook 2024
LP INFORMATION offers a latest published report on Autologous Cell Therapy Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Autologous Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Autologous Cell Therapy Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Autologous Cell Therapy Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Autologous Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in
Autologous Cell Therapy Market Demand by 2025: QY Research
This recently published report examines the global Autologous Cell Therapy market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Autologous Cell Therapy market along with its drivers, restraints, and trends. It also classifies the market into different
Autologous Cell Therapy Market : Trend, Analysis
Global Autologous Cell Therapy Market: Overview Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell
Autologous Cell Therapy Market: High Prevalence of Cancer Triggers Demand for Au …
Global Autologous Cell Therapy Market: Overview Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell
Autologous Cell Therapy Market: Unmet Medical Needs and Cost-effectiveness of Au …
Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell therapy does not even require